A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer

Lung Cancer

Volumn 28, Issue 2, 2000, Pages 157-162

  Weitz, John J ^a   Marschke Jr , Robert F ^b,h   Sloan, Jeff A ^b   Grill, Joseph P ^b   Jett, James R ^b   Knost, James A ^c   Hatfield, Alan K ^d   Zenk, David W ^e   Bate, Walter W ^f   Schaefer, Paul L ^g  

^a CentraCare Clinic   (United States)

^b MAYO CLINIC   (United States)

^c Illinois Oncol Res Assoc CCOP   (United States)

^d Carle Cancer Center CCOP   (United States)

^e Cedar Rapids Oncology Project CCOP   (United States)

^f Iowa Oncology Research Association CCOP   (United States)

^g Toledo Comm Clin Oncology Program   (United States)

^h LRMCC Northern Colorado   (United States)

Author keywords

Cell carcinoma; Lung cancer; Topotecan

Indexed keywords

TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETHARGY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALAISE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 0034192142     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00128-2     Document Type: Article

References (11)

1. Pocock S.L., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 31:1975;103-115.
2. Duffy D.E., Santner T.J. Confidence intervals for a binomial parameter based on multistage tests. Biometrics. 43:1987;81-93.
3. Kaplan E., Meier P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 53:1958;457-481.
4. Perez-Soler R., Fossella F.V., Glisson B.S. et al: Phase II study of topotecan in patients with advanced non small-cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol. 14(2):1996;503-513.
5. Perez-Soler R., Khuri F., Pisters K.M. et al. Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy. (meeting abstract). Proc. Am. Soc. Clin. Oncol. 16:1997;1619.
6. Lynch T.J., Kalish L., Strauss G. Phase II study of topotecan in metastatic non small cell lung cancer. J. Clin. Oncol. 12(2)(347):1994;52.
7. Kindler H.L., Kris M.G., Smith I.E., Slevin M.L., Krebs J.B. Continuous infusion topotecan as first-line therapy in patients with non small cell lung cancer (NSCLC): a phase II study. (meeting abstract). Proc. Am. Soc. Clin. Oncol. 16:1997;1697.
8. Mainwaring P.N., Nicolson M.C., Hickish T. et al. Continuous infusional topotecan in advanced breast and non small cell lung cancer: no evidence of increased efficacy. Br J. Cancer. 76(12):1997;1636-1639.
9. Wiesenfeld M., Marks R., Grill J. et al. A randomized phase II study of topotecan (TOPA) and cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel (Taxol®) with filgrastim in patients with advanced non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 16:1997;1755.
10. Rowinsky E.K., Kaufmann S.H., Baker S.D. et al. Sequences of topotecan and cisplatin: phase I, pharmacologic and in vitro studies to examine sequence dependence. J. Clin. Oncol. 14(12):1996;3074-3084.
11. Kozelsky T.K., Bonner J.A. Sequence dependent interaction of etoposide and topotecan (meeting abstract). Proc. Am. Assoc. Cancer Res. 36:1995;A1744.